Physician profile
Yonah J Hamlet
NPI 1174551519
$2,897.66
in general payments reported to CMS, 2019-2025
11 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $135 · 2021: $413 · 2022: $177 · 2023: $850 · 2024: $449 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,478.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $628.53 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $505.40 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Horizon Therapeutics Plc | $307.75 | 2022-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $293.83 | 2019-2021 | |
| Allergan, INC. | $278.20 | 2019-2020 | |
| Astellas Pharma US INC | $250.00 | 2023-2024 | Izervay |
| Alcon Vision LLC | $182.89 | 2019-2023 | Rhopressa, Simbrinza, Rocklatan |
| Abbvie INC. | $173.29 | 2023-2025 | |
| Amgen INC. | $132.56 | 2024 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2022 | |
| Thea Pharma INC. | $20.21 | 2024 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yonah Hamlet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.